Zanoterone

http://dbpedia.org/resource/Zanoterone an entity of type: Thing

Zanoterone (INN, USAN) (former developmental code name WIN-49596), also known as (5α,17α)-1'-(methylsulfonyl)-1'-H-pregn-20-yno[3,2-c]pyrazol-17-ol, is a steroidal antiandrogen which was never marketed. It was investigated for the treatment of benign prostatic hyperplasia (BPH) but failed to demonstrate sufficient efficacy in phase II clinical trials, and also showed an unacceptable incidence rate and severity of side effects (e.g., breast pain and gynecomastia). As such, it was not further developed. rdf:langString
rdf:langString Zanoterone
xsd:integer 41568288
xsd:integer 1093428331
xsd:integer 23
xsd:integer 107000
xsd:integer 2079581
xsd:integer 8020541
rdf:langString D06357
xsd:integer 32
xsd:integer -1
rdf:langString D06357
xsd:integer 2
xsd:integer 3
xsd:integer 9844827
xsd:integer 1
rdf:langString C[C@]12CC[C@H]3[C@H]CC[C@@H]4[C@@]3C
xsd:integer 1
rdf:langString MHDDZDPNIDVLNK-ZGIWMXSJSA-N
rdf:langString WIN-49596; -1'--1'-H-pregn-20-yno[3,2-c]pyrazol-17-ol
rdf:langString XQ5V1W49JG
xsd:integer 250
rdf:langString Zanoterone (INN, USAN) (former developmental code name WIN-49596), also known as (5α,17α)-1'-(methylsulfonyl)-1'-H-pregn-20-yno[3,2-c]pyrazol-17-ol, is a steroidal antiandrogen which was never marketed. It was investigated for the treatment of benign prostatic hyperplasia (BPH) but failed to demonstrate sufficient efficacy in phase II clinical trials, and also showed an unacceptable incidence rate and severity of side effects (e.g., breast pain and gynecomastia). As such, it was not further developed. Zanoterone was derived from 5α-dihydroethisterone (5α-dihydro-17α-ethynyltestosterone). It is an antagonist of the androgen receptor (Ki = 2.2 μM; RBA compared to metribolone = 2.2%), and with the exception of antiprogestogenic activity in rat and rabbit models, is devoid of other hormonal activities. Zanoterone does not inhibit 5α-reductase, aromatase, or 3α- or 3β-hydroxysteroid dehydrogenase in vitro. The drug significantly increases testosterone and estradiol levels in men. Zanoterone has been found to not significantly inhibit mating performance or fertility in adult male rats at high dosages for an extended period of time. It has been found to act as an inducer of the enzyme CYP3A4 in vivo in rats.
xsd:nonNegativeInteger 7470
xsd:string 107000-34-0
xsd:string 2079581
xsd:string D06357
xsd:string XQ5V1W49JG
xsd:string D06357
xsd:string 9844827

data from the linked data cloud